2086178-00-7
Chemical Structure
Vemircopan
Synonym(s): ALXN2050; ACH 0145228; ACH-5228
- CAS No.: 2086178-00-7
- Formula:C29H28BrN7O3
- Molecular Weight:602.48
IUPAC Name: (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
InChIKey: OCXAGXCMZACNEC-CTWZREHQSA-N
SMILES: C[C@]12[C@](C2)([H])N([C@@H](C1)C(NC3=C(C=CC(Br)=N3)C)=O)C(CN4C5=CC=C(C6=CN=C(C)N=C6)C=C5C(C(C)=O)=N4)=O
Biological Activity: Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vemircopan | 98.61% | Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Browett P J, et al. Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: interim data from a phase 2 open-label proof-of-concept study[J]. Blood, 2022, 140(Supplement 1): 717-719.
- [2]. Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. 2024 May 16:1-11. [Content Brief]
- [3]. Versino F, et al. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. Int J Lab Hematol. 2024 May;46 Suppl 1:43-54. [Content Brief]
